As expected, DT demonstrated a significant association with marijuana use coping motives (t = −4.51, β = −.33, sr2 = .13, p < .001), beyond the variance contributed by marijuana use frequency and non-criterion marijuana use motives. Furthermore, as predicted, the association between PTS symptom severity and marijuana use coping motives levels diminished significantly with the inclusion of DT in the model (β decreased from .27 to .12; sr2 decreased from .10 to .01), rendering it statistically non-significant (p > .01). These findings suggest that DT partially mediated the association between PTS symptom severity and marijuana use coping motives (Kenny, Kashy, & Bolger, 1998).
